The Adipose Tissue at the Crosstalk Between EDCs and Cancer Development.
adipose tissue
cancer
endocrine disrupting chemicals
endocrine disruptor (EDC)
model
secretome
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
04
2021
accepted:
30
06
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Obesity is a major public health concern at the origin of many pathologies, including cancers. Among them, the incidence of gastro-intestinal tract cancers is significantly increased, as well as the one of hormone-dependent cancers. The metabolic changes caused by overweight mainly with the development of adipose tissue (AT), insulin resistance and chronic inflammation induce hormonal and/or growth factor imbalances, which impact cell proliferation and differentiation. AT is now considered as the main internal source of endocrine disrupting chemicals (EDCs) representing a low level systemic chronic exposure. Some EDCs are non-metabolizable and can accumulate in AT for a long time. We are chronically exposed to low doses of EDCs able to interfere with the endocrine metabolism of the body. Importantly, several EDCs have been involved in the genesis of obesity affecting profoundly the physiology of AT. In parallel, EDCs have been implicated in the development of cancers, in particular hormone-dependent cancers (prostate, testis, breast, endometrium, thyroid). While it is now well established that AT secretes adipocytokines that promote tumor progression, it is less clear whether they can initiate cancer. Therefore, it is important to better understand the effects of EDCs, and to investigate the buffering effect of AT in the context of progression but also initiation of cancer cells using adequate models recommended to uncover and validate these mechanisms for humans. We will review and argument here the potential role of AT as a crosstalk between EDCs and hormone-dependent cancer development, and how to assess it.
Identifiants
pubmed: 34354670
doi: 10.3389/fendo.2021.691658
pmc: PMC8329539
doi:
Substances chimiques
Endocrine Disruptors
0
Environmental Pollutants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
691658Informations de copyright
Copyright © 2021 Bokobza, Hinault, Tiroille, Clavel, Bost and Chevalier.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2019 Feb 15;202(4):1265-1286
pubmed: 30659108
Nat Rev Endocrinol. 2010 Jul;6(7):363-70
pubmed: 20498677
Environ Int. 2019 Nov;132:105028
pubmed: 31382183
J Cell Physiol. 2019 Mar;234(3):2399-2425
pubmed: 30192004
Environ Health Perspect. 2015 Apr;123(4):317-23
pubmed: 25493337
Endocr Dev. 2010;19:45-52
pubmed: 20551667
Cancer Causes Control. 2011 Jul;22(7):977-83
pubmed: 21562753
Nutr Res. 2017 Feb;38:13-26
pubmed: 28381350
Cell Death Differ. 2021 Jan;28(1):35-51
pubmed: 32494027
Dev Biol. 2021 Jul;475:37-53
pubmed: 33684433
Endocrinology. 2020 Jun 1;161(6):
pubmed: 32170302
Oncotarget. 2017 May 2;8(18):30606-30616
pubmed: 28389628
Nature. 2020 Oct;586(7828):275-280
pubmed: 33029001
Cancer Metastasis Rev. 2015 Dec;34(4):765-73
pubmed: 26363603
PLoS One. 2014 Sep 11;9(9):e106495
pubmed: 25211159
Lab Chip. 2015 Feb 7;15(3):735-44
pubmed: 25428803
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Nat Commun. 2016 Jan 12;7:10230
pubmed: 26756352
Environ Res. 2014 Aug;133:170-7
pubmed: 24949816
Endocrinology. 2014 Mar;155(3):805-17
pubmed: 24424067
BMC Biomed Eng. 2019;1:
pubmed: 32133436
J Cell Biochem. 2018 Feb;119(2):2333-2344
pubmed: 28885729
Biochem Biophys Res Commun. 2004 Mar 5;315(2):255-63
pubmed: 14766202
Gynecol Oncol. 2010 Oct;119(1):65-9
pubmed: 20674961
Rev Urol. 2005;7 Suppl 3:S4-S10
pubmed: 16985878
Crit Rev Toxicol. 2014 May;44 Suppl 1:1-81
pubmed: 24793953
Sci Rep. 2021 Jan 11;11(1):320
pubmed: 33431998
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1509-14
pubmed: 16896041
Nat Protoc. 2020 Jan;15(1):15-39
pubmed: 31853056
Oncotarget. 2017 Dec 4;8(67):111780-111794
pubmed: 29340091
JCI Insight. 2017 Feb 23;2(4):e87489
pubmed: 28239646
Endocrinology. 2014 Mar;155(3):656-8
pubmed: 24564415
Cell. 2016 Jun 16;165(7):1586-1597
pubmed: 27315476
Int J Environ Res Public Health. 2017 Mar 22;14(3):
pubmed: 28327540
Reprod Toxicol. 2021 Aug;103:108-123
pubmed: 34102259
Reprod Toxicol. 2017 Mar;68:3-33
pubmed: 27760374
J Clin Invest. 1989 Nov;84(5):1663-70
pubmed: 2681273
BMC Biomed Eng. 2020 Apr 30;2:6
pubmed: 32903358
J Clin Invest. 2011 Jun;121(6):2094-101
pubmed: 21633177
Environ Health Perspect. 2008 Jun;116(6):761-8
pubmed: 18560532
Cell Metab. 2021 Mar 2;33(3):499-512.e6
pubmed: 33596409
Int J Mol Sci. 2020 May 21;21(10):
pubmed: 32455722
Metab Brain Dis. 2019 Feb;34(1):141-152
pubmed: 30302719
Int J Mol Sci. 2019 May 13;20(9):
pubmed: 31085992
Nat Commun. 2016 May 31;7:11674
pubmed: 27241286
Front Endocrinol (Lausanne). 2017 Jan 09;7:171
pubmed: 28119665
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):3-13
pubmed: 22453214
Environ Health Perspect. 2013 Feb;121(2):162-9
pubmed: 23221922
Nat Protoc. 2020 Oct;15(10):3380-3409
pubmed: 32929210
Ecotoxicol Environ Saf. 2019 Mar;169:564-572
pubmed: 30476818
Endocr Rev. 2015 Dec;36(6):E1-E150
pubmed: 26544531
Oncotarget. 2017 May 20;8(34):57622-57641
pubmed: 28915700
NPJ Breast Cancer. 2017 Sep 21;3:37
pubmed: 28948213
N Engl J Med. 2011 Oct 6;365(14):1304-14
pubmed: 21991952
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Front Endocrinol (Lausanne). 2021 Jan 26;11:600404
pubmed: 33574796
J Cell Physiol. 2006 Apr;207(1):12-22
pubmed: 16110483
Front Endocrinol (Lausanne). 2019 Mar 01;10:112
pubmed: 30881345
BJU Int. 2003 May;91(7):716-20
pubmed: 12699491
Annu Rev Physiol. 2013;75:225-40
pubmed: 23043248
Nat Rev Endocrinol. 2019 Sep;15(9):507-524
pubmed: 31296970
Endocr Rev. 2012 Jun;33(3):378-455
pubmed: 22419778
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
Environ Int. 2018 Dec;121(Pt 2):1113-1120
pubmed: 30390924
Stem Cells Int. 2021 Feb 11;2021:2179429
pubmed: 33628265
Int J Urol. 2010 Apr;17(4):369-76
pubmed: 20409231
Environ Sci Technol. 2019 Mar 19;53(6):3287-3295
pubmed: 30785727
Rev Endocr Metab Disord. 2020 Mar;21(1):127-147
pubmed: 31792807
Br J Cancer. 2020 Oct;123(8):1336-1344
pubmed: 32728095
Int J Cancer. 2012 Jan 1;130(1):241-2
pubmed: 21312194
Carcinogenesis. 2016 Dec;37(12):1144-1151
pubmed: 27742691
Ann Endocrinol (Paris). 2015 Jul;76(3):253-9
pubmed: 25934356
Lancet. 2016 Aug 20;388(10046):776-86
pubmed: 27423262
J Clin Med. 2019 Jun 14;8(6):
pubmed: 31208019
J Clin Oncol. 2010 Jul 20;28(21):3457-62
pubmed: 20566993
Compr Physiol. 2017 Dec 12;8(1):237-282
pubmed: 29357128
Prostate. 2020 May;80(6):518-526
pubmed: 32084293
Environ Int. 2021 Jun;151:106400
pubmed: 33611106
J Appl Toxicol. 2018 Mar;38(3):398-407
pubmed: 29094436
Sci Rep. 2019 May 10;9(1):7250
pubmed: 31076601
World J Gastroenterol. 2008 Nov 14;14(42):6473-80
pubmed: 19030198
Endocrinology. 2008 Feb;149(2):565-73
pubmed: 18039775
Rev Endocr Metab Disord. 2015 Dec;16(4):359-64
pubmed: 26831296
Environ Health Perspect. 2013 Mar;121(3):318-23
pubmed: 23308854
Horm Mol Biol Clin Investig. 2016 Apr 1;26(1):25-42
pubmed: 26910750
Cytotechnology. 2020 Oct;72(5):665-683
pubmed: 32524217
Sci Total Environ. 2020 Dec 15;748:142458
pubmed: 33113674
Lancet Diabetes Endocrinol. 2020 Aug;8(8):703-718
pubmed: 32707118
Endocr Relat Cancer. 2020 Dec;27(12):711-729
pubmed: 33112829
Biosci Biotechnol Biochem. 2015;79(4):636-9
pubmed: 25516096
Endocr Rev. 2009 Jun;30(4):293-342
pubmed: 19502515
Toxicol Lett. 2018 Dec 15;299:21-31
pubmed: 30172001
Biochim Biophys Acta. 2014 Mar;1842(3):520-33
pubmed: 23735214
Endocr Rev. 2011 Aug;32(4):550-70
pubmed: 21642230
Cancer Lett. 2006 Jun 8;237(1):109-14
pubmed: 16019138
Mol Cell Endocrinol. 2017 Dec 5;457:35-42
pubmed: 28257827
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:89-106
pubmed: 30044726
Int J Cancer. 2020 Feb 1;146(3):657-663
pubmed: 30892691
J Cell Biochem. 2016 Jul;117(7):1697-706
pubmed: 26666522
Mol Cancer Res. 2019 Mar;17(3):821-835
pubmed: 30606769
Biomaterials. 2017 Jun;130:76-89
pubmed: 28364632
Cancer Biol Med. 2016 Mar;13(1):101-19
pubmed: 27144066
Toxicol Lett. 2019 Jun 1;307:59-71
pubmed: 30831249
Environ Health Perspect. 2012 Apr;120(4):508-14
pubmed: 22262711